Three scientists are honored for developing a class of blockbuster weight-loss drugs. Is a Nobel prize on the way?

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

Native GLP-1, however, is rapidly inactivated by dipeptidyl peptidase 4; therefore, a continuous infusion would be required to achieve a clinical effect. Liraglutide is a GLP-1 analog, which is ...

A Cleveland Clinic study showed that in patients with type 2 diabetes, obesity, and chronic kidney disease, bariatric surgery ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...

When you take GLP-1 medications, they bind to GLP-1 receptors on your pancreas ... Furthermore, semaglutide was more effective than liraglutide for chronic weight management.

The structure of liraglutide (a structurally distinct analog of GLP-1RA) was found to be unfavorable for co-formulation with SNAC on account of its stronger membrane-binding properties ...

No such link was found between liraglutide GLP-1 drugs and suicidal ideation. National health authorities have so far found no connection between GLP-1 medications and suicidal thoughts ...

The lauded Lasker Awards, frequently tied to Nobel Prize acclaim, highlighted the significant accomplishments of three ...

A Cleveland Clinic study identified key factors that can impact the long-term weight loss of patients with obesity who were ...

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action. Semaglutide has the longest half-life of the three, which may provide ...